| scholarly article | Q13442814 |
| P2093 | author name string | Chen Qiu | |
| Min Chen | |||
| Tinghui Yin | |||
| Zhifei Dai | |||
| Rongqin Zheng | |||
| Enze Qu | |||
| Xiaoyou Wang | |||
| Xiaolong Liang | |||
| Yongjiang Mao | |||
| Chuang Gao | |||
| Yujia You | |||
| P2860 | cites work | Advances in imaging modalities in prostate cancer | Q38365187 |
| Growing indications for CEUS: The kidney, testis, lymph nodes, thyroid, prostate, and small bowel | Q38503572 | ||
| Conjugation of porphyrin to nanohybrid cerasomes for photodynamic diagnosis and therapy of cancer | Q40003053 | ||
| Cancer statistics in China, 2015. | Q40064386 | ||
| A history of photodynamic therapy | Q41152245 | ||
| Spatial Control of Gene Expression by Nanocarriers Using Heparin Masking and Ultrasound-Targeted Microbubble Destruction. | Q42330126 | ||
| Targeted delivery of CuS nanoparticles through ultrasound image-guided microbubble destruction for efficient photothermal therapy | Q43940425 | ||
| TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer | Q44314773 | ||
| Usefulness of perflubutane microbubble-enhanced ultrasound in imaging and detection of prostate cancer: phase II multicenter clinical trial | Q44383020 | ||
| Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy | Q47869311 | ||
| In situ conversion of porphyrin microbubbles to nanoparticles for multimodality imaging. | Q53018516 | ||
| Contrast-enhanced ultrasound (CEUS) for the evaluation of focal liver lesions - a prospective multicenter study of its usefulness in clinical practice. | Q53078119 | ||
| The EFSUMB Guidelines on the Non-hepatic Clinical Applications of Contrast Enhanced Ultrasound (CEUS): a new dawn for the escalating use of this ubiquitous technique. | Q53175745 | ||
| Treatment: When less is more. | Q53242576 | ||
| Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes | Q87711567 | ||
| Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen | Q24647328 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| The utility and limitations of contrast-enhanced ultrasound for the diagnosis and treatment of prostate cancer | Q28085279 | ||
| Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas | Q28574605 | ||
| Nucleic acid delivery with microbubbles and ultrasound. | Q30384749 | ||
| Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure | Q30408124 | ||
| State-of-the-art materials for ultrasound-triggered drug delivery | Q30409234 | ||
| Ultrasound-triggered release of materials entrapped in microbubble–liposome constructs: A tool for targeted drug delivery | Q30429680 | ||
| Microbubbles in ultrasound-triggered drug and gene delivery | Q30438994 | ||
| Nanobubbles for enhanced ultrasound imaging of tumors | Q30469828 | ||
| Mn-porphyrin conjugated Au nanoshells encapsulating doxorubicin for potential magnetic resonance imaging and light triggered synergistic therapy of cancer | Q30584584 | ||
| Photodynamic therapy for prostate cancer--a review of current status and future promise | Q33398502 | ||
| Image guidance for focal therapy of prostate cancer. | Q33724312 | ||
| Photodynamic therapy and anti-tumour immunity. | Q34105703 | ||
| Photodynamic therapy for cancer | Q34194073 | ||
| Addressing overdiagnosis and overtreatment in cancer: a prescription for change | Q35067706 | ||
| Theranostic porphyrin dyad nanoparticles for magnetic resonance imaging guided photodynamic therapy | Q35166995 | ||
| Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial | Q36231929 | ||
| Value of contrast-enhanced ultrasonography in prostate cancer | Q38012218 | ||
| EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. | Q38160994 | ||
| Understanding ultrasound induced sonoporation: definitions and underlying mechanisms | Q38165638 | ||
| Cardiovascular drug delivery with ultrasound and microbubbles | Q38187761 | ||
| Acoustic behavior of microbubbles and implications for drug delivery | Q38199325 | ||
| Multifunctional ultrasound contrast agents for imaging guided photothermal therapy | Q38208029 | ||
| Management of low risk prostate cancer-active surveillance and focal therapy | Q38211360 | ||
| Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity | Q38314457 | ||
| Nanoparticles in photodynamic therapy | Q38324623 | ||
| P433 | issue | 6 | |
| P921 | main subject | microbubble | Q6839290 |
| P304 | page(s) | 1665-1677 | |
| P577 | publication date | 2018-02-12 | |
| P1433 | published in | Theranostics | Q21051383 |
| P1476 | title | Porphyrin-grafted Lipid Microbubbles for the Enhanced Efficacy of Photodynamic Therapy in Prostate Cancer through Ultrasound-controlled In Situ Accumulation. | |
| P478 | volume | 8 |
Search more.